La Reunión Anual de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica) se llevará a cabo del 2 al 6 de junio. Los aspectos destacados de la investigación del día incluyen el uso de trastuzumab deruxtecán para tratar tumores positivos para HER2 (receptor 2 del factor de crecimiento epidérmico humano) y el uso de terapia de células T con CAR (receptor de antígeno quimérico) para ralentizar o detener el mieloma múltiple.

The ASCO Annual Meeting is being held June 2 to 6. Research highlights from the day include using trastuzumab deruxtecan to treat HER2-expressing tumors and using CAR T-cell therapy to slow or stop multiple myeloma.

Composer and multiple myeloma survivor Ed Hartman shares how having creative outlets like music and writing have helped him manage the mental and physical impacts of his cancer diagnosis and treatment.

In this podcast, members of the American Society of Clinical Oncology (ASCO) discuss new research presented at the 2022 ASCO Annual Meeting in multiple myeloma, breast cancer, and cancer in people age 60 or older.

A bone marrow/stem cell transplant is an effective treatment option for several cancers, even when the patient is older. Read how you and your doctor can determine if the treatment is right for you.

El informe Avances clínicos en oncología del año 2018 de la American Society of Clinical Oncology ha adjudicado su título de Avance del año a una inmunoterapia celular adoptiva. ¿De qué se trata este tratamiento innovador contra el cáncer? ¿Cuáles son los riesgos y los beneficios?

The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?

In this Voices on Cancer post, patient advocate and author Scott Joy discusses the power of connecting with the cancer community.